Ignite Creation Date:
2024-05-06 @ 10:27 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03267940
Status:
TERMINATED
Last Update Posted:
2020-02-07
First Post:
2017-07-25
Brief Title:
Study of PEGPH20 With Cisplatin CIS and Gemcitabine GEM PEGPH20 With Atezolizumab ATEZO CIS and GEM and CIS and GEM Alone in Participants With Previously Untreated Unresectable Locally Advanced or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Sponsor:
Halozyme Therapeutics
Organization:
Halozyme Therapeutics
Organization Data
Organization:
Halozyme Therapeutics
Class:
INDUSTRY
Study ID:
Halo-110-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Halozyme Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None